PRGO
Perrigo Company plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IE
$14.92
+4.56%Year over year
Reported trailing growth
- Revenue
- -4.2%
- EBITDA
- —
- EBIT
- -25.1%
- EPS
- —
- Free cash flow
- -31.8%
- Operating cash flow
- -31.2%
Forward estimates
Based on analyst estimates
- Revenue
- -3.2%
- EBITDA
- +169.7%
- EPS
- +118.9%
Three-year CAGR
- Revenue
- -1.5%
- EBITDA
- —
- EBIT
- +63.3%
- Net income
- —
- EPS
- —
- Free cash flow
- -11.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026